ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1099

Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder

Maria Salgado Guerrero1 and Angelo Gaffo2, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL

Meeting: ACR Convergence 2023

Keywords: Education, Eye Disorders, prevention, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1082–1099) Measures & Measurement of Healthcare Quality Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College of Ophthalmology (ACO) guidelines published in 2016 recommends using a maximum HCQ daily dose of ≤5mg/kg of actual body weight and to begin annual retinopathy screening after 5 years of HCQ use with automated visual fields plus optical coherence tomography (OCT). The aim of this quality improvement project was to assess if an educational intervention could improve the adherence to ACO dosing recommendations and retinal toxicity monitoring in a large VA Medical Center.

Methods: Patients above 18 years old with a connective tissue disorder diagnosis and who were actively using HCQ were evaluated. HCQ dosing above 5 mg/kg, and eye screening status were reviewed. Two different interventions were implemented twelve months apart: 1) An educational intervention using a personal email with the ACO guidelines was sent to each provider with patients requiring screening testing or HCQ dose adjustment. 2) Second intervention using a “system alert” in the medical record with the correct HCQ dosing and annual OCT was created as a reminder when prescribing or renewing HCQ. Changes in compliance from pre- to post-interventions were assessed.

Results: A total of 258 patients with an active HCQ prescription were included. Forty patients (15%) had a HCQ dose above 5mg/kg. Among this group, HCQ was mainly prescribed by a Rheumatologist (35/40).From the forty patients with HCQ dose above 5mg/kg, 24 (60%) had at least one OCT screening. After the first intervention, the number of patients who required HCQ dose adjustment went down by 5% (15% vs 10%). Most of the patients who required HCQ dose adjustment were receiving a HCQ dose between 5-5.9 mg/kg (60%). More patients had an updated OCT (75% post vs 60% pre). After the second intervention, the number of patients who required HCQ dose adjustment went up by 4%. However, more patients had an updated OCT (90% post vs 75% pre) (Figure).

Conclusion: Educational interventions, including the review of guidelines, or system alerts on different medical records were associated with a notable improvement in retinal toxicity screening but had modest or no effect on adherence to ACO HCQ dosing recommendations.

Supporting image 1

Percentage of patients with HCQ dose >5mg/kg and OCT overtime


Disclosures: M. Salgado Guerrero: None; A. Gaffo: None.

To cite this abstract in AMA style:

Salgado Guerrero M, Gaffo A. Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/improving-hydroxychloroquine-dosing-and-eye-screening-compliance-in-patients-with-connective-tissue-disorder/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-hydroxychloroquine-dosing-and-eye-screening-compliance-in-patients-with-connective-tissue-disorder/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology